TADA3: A Potential Drug Target and Biomarker for Transcriptional Adaptation

Target Name: TADA3

NCBI ID: G10474

TADA3

TADA3: A Potential Drug Target and Biomarker for Transcriptional Adaptation

Abstract:
Transcriptional adapter 3 (TADA3) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression. Research has identified TADA3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This article summarizes the current understanding of TADA3, its potential drug implications, and the progress made in the search for biomarkers associated with TADA3 dysfunction.

Introduction:
RNA molecules are the building blocks of life, and their folding and stability are regulated by various factors, including the interactions between RNA secondary structures and the cytoplasmic environment. Transcriptional adapter proteins are involved in the process of RNA folding and stability, ensuring the accurate translation of genetic information from the DNA to the RNA molecule. TADA3, a non-coding RNA molecule, is one of these adapters that has been extensively studied for its role in gene regulation.

Potential Drug Targets:
TADA3 has been identified as a potential drug target for various diseases due to its involvement in the regulation of gene expression. Its functions in RNA metabolism have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Drugs that target TADA3 have the potential to modulate its activity, leading to therapeutic benefits. For instance, inhibitors of TADA3 have been shown to enhance the translation of certain genes, leading to increased protein expression and therapeutic benefits in cancer and neurodegenerative diseases. Additionally, Modulators of TADA3 have been shown to improve the stability of RNA molecules, reducing the risk of RNA-protein misfolding and improving the overall quality of RNA products.

Biomarkers:
TADA3 has also been identified as a potential biomarker for various diseases. Its expression levels have been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. This suggests that TADA3 may serve as a useful biomarker for these diseases, and that its levels may be a valuable diagnostic target for personalized medicine.

Pathophysiology:
TADA3 plays a crucial role in the regulation of gene expression, specifically in the process of post-transcriptional regulation (PTRNA) folding. PTRNA folding is the process by which RNA molecules are processed and modified to create stable and functional RNA products. TADA3 is involved in the regulation of various cellular processes, including the stability of mRNAs, microRNA (miRNA) expression, and the regulation of translation efficiency.

TADA3 dysfunction has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Studies have shown that TADA3 levels are altered in these diseases, and that its dysfunction may contribute to the pathophysiology of these conditions. For instance, TADA3 has been shown to be involved in the regulation of cancer cell growth and progression, and its inhibition has been shown to result in therapeutic benefits in cancer treatment.

Conclusion:
TADA3 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and has been identified as a potential drug target and biomarker for various diseases. Its functions in RNA metabolism have been implicated in the development and progression of these conditions , and its dysfunction may contribute to the pathophysiology of these diseases. Further research is needed to fully understand the role of TADA3 in disease progression and to develop effective therapies that target its activity.

Protein Name: Transcriptional Adaptor 3

Functions: Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex. Also known as a coactivator for p53/TP53-dependent transcriptional activation. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4

The "TADA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TADA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets